Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
Moated ASX share crashes amid weak trading update
stocks
A collection of our best stock opportunities
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,015.40 | 48.70 | 0.54% |
CAC 40 | 7,861.96 | 4.60 | 0.06% |
DAX 40 | 24,262.22 | 44.85 | 0.19% |
Dow JONES (US) | 44,636.18 | 3.19 | 0.01% |
FTSE 100 | 9,136.94 | 0.62 | 0.01% |
HKSE | 25,176.93 | 347.52 | -1.36% |
NASDAQ | 21,185.87 | 87.57 | 0.42% |
Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
S&P 500 | 6,382.88 | 12.02 | 0.19% |
S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
SSE Composite Index | 3,615.72 | 6.01 | 0.17% |